A drug (Surovatamig) after first-line treatment for chronic lymphocytic leukaemia or small lymphocytic lymphoma

You may qualify if

• Documented diagnosis of CLL/SLL with genomic features defined by unmutated IGHV.
• Treatment received and response at the end of 1L (first-line) finite therapy.
• Participants with SLL (except those in CR in Phase III part) must have measurable disease (nodal or extranodal) with at least one measurable target lesion.
• ECOG performance status of 0 to 2.
• Adequate haematologic, liver, renal and cardiac function.
• Female participants: must be either women not of childbearing potential or must use a highly effective form of contraception.
• Male participants who intend to be sexually active with females of childbearing potential must agree to use barrier contraception (eg, condoms).

You can't join if

• Suspected or confirmed transformation of CLL/SLL to a more aggressive form of lymphoma (ie, Richter's transformation, prolymphocytic leukaemia, or DLBCL).
• Evidence of active or history of Central Nervous System (CNS) involvement by CLL/SLL.
• History of or ongoing confirmed progressive multifocal leukoencephalopathy.
• Participants who have any concurrent or history of malignancy.
• Participants with: Active or uncontrolled infection (including Epstein-Barr virus-EBV) requiring systemic therapy.
• Participants with known history of Heamophagocytic lymphohistiocytosis (HLH).
• Human Immunodeficiency Virus (HIV) infection, or participants with chronic or active infection with Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV).
• Major cardiac abnormalities.
• Prior CLL/SLL-specific therapies.
• Requires chronic immunosuppressive therapy for active autoimmune/inflammatory condition or prior allogeneic stem cell or solid organ transplant.
• Major surgical procedure.
• Known hypersensitivity to surovatamig or any of the excipients of the product.